OAd-TNF-α-IL2 delivers the pro-T-cell cytokines IL-2 and TNF-α in the immunosuppressive TME of pancreatic cancer, and enhances the antitumor efficacy of mesothelin-CAR T-cell therapy [78] (Fig. 6A). This evidence concerns the gene TNF and familial pancreatic carcinoma.